Skip to content

Impact of Early Rupture of the Residual Membrane on Latency Before Labour Begins

Impact of Early Rupture of the Residual Membrane on Latency Before Labour Begins

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07301957
Acronym
RESIRUPT
Enrollment
130
Registered
2025-12-24
Start date
2026-03-24
Completion date
2028-03-24
Last updated
2026-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prelabor Rupture of Membranes

Keywords

prelabor rupture of membranes

Brief summary

Approximately 25% of patients experience premature rupture of membranes before labour. Of these patients, 82% will give birth within 24 hours and 97% within 48 hours. Patients who do not go into labour spontaneously will be induced 24 or 48 hours after their membranes rupture, depending on the centre. During this period, they are hospitalised in the obstetrics department. The presence of a residual membrane appears to prolong the latency period before labour begins and the rate of induction, according to a pilot study conducted by investigator. No study specifically addresses this topic. The various studies on "Rupture of Membranes Before Labour" assess its frequency of occurrence or the time before considering induction. They also assess the occurrence of maternal-foetal infection. This is no longer of interest today, as antibiotic prophylaxis has significantly reduced maternal-foetal infections. Investigator would therefore like to assess the impact of additional rupture of the residual membrane upon the patient's admission on the latency before labour and the induction rate (for membrane rupture exceeding 48 hours.

Interventions

OTHERAdditional rupture of the residual membrane

Additional rupture of the residual membrane using a sterile, single-use amniotic membrane piercer such as the Robé device

Sponsors

Centre Hospitalier le Mans
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Women over 18 years of age * Single foetal pregnancy, cephalic presentation * diagnosis of membrane rupture with persistence of one membrane and absence of immediate spontaneous labour. * Person affiliated with or beneficiary of a social security scheme * Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).

Exclusion criteria

* Minor patient * patient under guardianship/curatorship, * multiple pregnancy, pregnancy with foetal death * non-cephalic presentation * gestational age less than 37 weeks, * rupture of membranes more than 12 hours ago * contraindication to vaginal deliver * meconium-stained amniotic fluid, * clinical signs suggestive of intrauterine infection (maternal hyperthermia \>38°C, maternal and/or foetal tachycardia, purulent amniotic fluid), * cervix not accessible for artificial rupture * vaginismus * contraindication to a potential expectant management * indication for induction for another reason

Design outcomes

Primary

MeasureTime frameDescription
Latency between the rupture of membranes and the onset of labourAt labour onset (up to 6 days)Latency is evaluated by the time in minutes between the rupture of membranes and the onset of labour. The diagnosis of rupture is the spontaneous loss of fluid through the vagina. The diagnosis of labour is defined by the onset of painful uterine contractions and cervical changes. The time recorded will be when the patient's cervix is 3 cm dilated.

Secondary

MeasureTime frameDescription
Trigger rate for prolonged rupture of membranes48 hours after rupture of membranesTrigger rate for prolonged rupture of membranes was evaluated by absence of spontaneous labour 48 hours after the time H0 defined during the initial consultation (rupture of membrane's diagnosis)

Countries

France

Contacts

CONTACTChristelle JADEAU
recherchecliniquepromotion@ch-lemans.fr+33244710204
PRINCIPAL_INVESTIGATORMarie-Charlotte FAURANT, MD

Centre Hospitalier le Mans

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 2, 2026